0947 GMT - AstraZeneca is among the most mentioned companies across news items over the past six hours, according to Factiva data. The Anglo-Swedish company said the U.S. drug regulator approved its drug Lynparza as a prostate cancer treatment, and also that it has decided to discontinue the development of another drug for inflammatory bowel disease. Lynparza was approved for the treatment of metastatic castration-resistant prostate cancer after success in a phase-3 trial. The treatment will be administered in combination with abiraterone and prednisone, the company said. Separately, AstraZeneca said it has discontinued the development of monoclonal antibody brazikumab for the treatment of inflammatory bowel disease, citing the competitive landscape in drug development. Dow Jones & Co. owns Factiva. (cecilia.butini@wsj.com)

 

(END) Dow Jones Newswires

June 01, 2023 06:02 ET (10:02 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Set 2023 a Ott 2023 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Ott 2022 a Ott 2023 Clicca qui per i Grafici di Astrazeneca